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ABSTRACT                        The appearance, the individual distribution and the pattern of colocalization
of nitric oxide synthase (NOS-immunoreactivity, NOSi), vasoactive intestinal peptide (VIP-
immunoreactivity, VIPi) and neuropeptide Y (NPY-immunoreactivity, NPYi) immunoreactivity
were examined in the developing human fetal small intestine at weeks 12 and 18 of gestation.
Neurons expressing VIPi, NPYi and NOSi were observed in the small intestine of the 12-week-
old human fetuses and from this age on a gradual increase in the immunoreactivities appeared
until week 18 of gestation when a dense network of immunopositive fibres and cell bodies
were observed both in the submucous (SmP) and in the myenteric plexuses (MP). The double-
labelling immunocytochemistry showed different pattern of the overlapping immunoreactive
structures within the myenteric and submucous plexuses. The cellular colocalization of VIPi and
NOSi in submucous ganglia were revealed around week 12 of gestation while in the myenteric
ganglia cells with overlapping immunoreactivity appeared around week 18. A limited cellular
colocalization of NPYi and NOSi were noticed before week 18, and NOSi neurons in the MP
of the 12-week-old fetuses were preferentially innervated by NPYi varicosities. These results
suggest that VIP, NPY and NO may exert a cooperative action in human fetal gastrointestinal
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Detailed studies about the ontogeny of peptide-containing
neurons in the human enteric nervous system (ENS) were
performed (Bryant et al. 1982; Larsson et al. 1987) and it is
known that neuronal elements expressing VIP or NPY appear
during early fetal development. Many studies have suggested
that VIP containing neurons are important mediators of the
descending inhibitory phase of peristalsis (Larsson et al.
1976; Hata et al.1990; Furness et al. 1992; Grider and Jin
1993; Allesher and Daniel 1994). Other evidence indicates
that the mediation of descending inhibition is not limited to
VIP and suggests that nitric oxide (NO) may also serve as an
inhibitory neurotransmitter (Giorgio et al. 1994; Yuan et al.
1995; Young et al. 1995). Recent evidence indicates that NPY
is present in inhibitory motor neurons of guinea pig mye/
nteric ganglia (Uemura et al. 1995). The wide distribution of
neurons with NPYi suggests that just like VIP, NPY is also
involved as an inhibitory neurotransmitter in all regions of
the fetal gut. There are two populations of NPY immu-
noreactive nerve fibres in the gut. One major population of
fibres is of intrinsic origin, distributed in all layers of the gut
(Sundler et al. 1993). A minor population of NPY fibres, with
extrinsic origin, is identical with the adrenergic NPY fibres
distributed mainly around blood vessels and in the myenteric
ganglia (Lundberg et al. 1982; Browning et al. 1999).
Colocalization studies showing that NO is produced in
enteric neurons that express neuropeptides including VIP
(Costa et al. 1992) and  NPY (Kirchgessner et al. 1994) make
VIP, NPY and NO viable candidates as parallel neurotrans-
mitters.
The early appearance of neuronal elements with VIP,
NPY and NOS immunoreactivity is well documented in
human fetal intestine (Bryant et al. 1982; Chayvialle et al.
1983; Larsson et al. 1987; Timmermans et al. 1994). Since
most of these investigations were performed on sections, they
do not give informations about the distribution of nerve fibres
and cell bodies within the different compartments of the
human fetal ENS. Studies as concerns the possible co-
localization of VIPi with NOSi or NPYi with NOSi during
the development of the human ENS do not exist. The first aim
of these investigations was therefore to determine the indi-
vidual distribution of VIPi, NPYi and NOSi within the human
fetal ENS using wholemount preparations of the intestinal
wall. The second aim was to investigate in what extent these
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substances are colocalized in the developing human fetal
small intestine. The third aim was to examine changes in the
distribution of the overlapping immunoreactive neuronal
elements between weeks 12 and 18 of gestation.
The present study provides the first evidence on the
simultaneous appearance of NOSi with VIPi and NOSi with
NPYi in different neuronal populations in the developing
human fetal small intestine.
Materials and Methods
Tissues
Intestinal segments of human fetuses (weeks 12 and 18 of
gestation) were obtained immediately after legally approved
or spontaneous abortions. The crown-heel length was used
to assign gestation age. Three fetuses of all ages were used
for each examination. The experiments were performed in
accordance with the declaration of the Medical World
Federation proclaimed in Helsinki in 1964.
Immunocytochemistry
Segments of small intestine were ligated and distended using
a modified Zamboni fixative (Scheuermann et al. 1987) and
fixed overnight at 4oC. After washing with phosphate buff-
ered saline (PBS) at pH 7.4, tissue pieces were used for
wholemount preparations and cryosections. Double-labelling
immunofluorescence histochemistry was performed applying
simultaneous incubation using a monoclonal mouse anti-
NOS antiserum (Affinity, Menasha, USA; final dilution
1:200) in combination with either a rabbit anti-VIP (Affinity;
final dilution 1:200) or a rabbit anti-NPY antiserum (Amer-
sham; final dilution 1:500) overnight at room temperature.
After incubation with primary antisera wholemounts were
washed with PBS and exposed for 6 h to a mixture of species-
specific secondary antibodies conjugated to FITC (Jackson,
Baltimore, USA; final dilution 1:100), Cy3 (Sigma, Buda-
pest, Hungary; final dilution 1:200) or biotin (Amersham,
Backinghamshire, England; final dilution 1:100). After
incubation in secondary antiserum, tissues were washed and
incubated for overnight with streptavidin-Texas Red (Amer-
sham; final dilution 1:100) or streptavidin-biotinylated
horseradish peroxidase (Amersham; final dilution 1:100).
Specimens were mounted in PBS-buffered glycerol. Prepara-
tions were viewed and photographed with a Zeiss Axioscope
2 MOT fluorescent microscope equipped with a Zeiss Axio-
Cam digital camera.
Results
The individual distribution and the pattern of coexistence of
NOSi, VIPi and NPYi were examined in cryosections and in
wholemount preparations of human fetal small intestine
between weeks 12 and 18 of gestation. NOS, VIP and NPY
immunoreactive structures were observed in each part of the
small intestine at week 12 of gestation (Figs. 1 and 2). From
this age on there was a gradual increase in the intensity of
immunofluorescence, and also in the number and the diversi-
ty of the immunopositive nerve structures until week 18 of
gestation, when dense networks of immunopositive fibres
and large number of immunopositive cell bodies were seen
(Fig. 3). Most of the peptide-containing intraganglionic fibres
expressing either VIP or NPY were distributed within the
myenteric plexus (MP) as varicose fibres and freqently
formed baskets around non-immunopositive cell bodies
(Figs. 1D, F and 2D, 2F). NOSi fibres within the MP showed
a dense, less structured pattern of fibres with rare varicosities
which never formed baskets around non-immunopositive cell
bodies (Fig. 2A). Both peptidergic and nitrergic neuronal
structures were less densely distributed in the submucosus
plexus (SmP), although varicose fibres and cell bodies with
VIPi are frequently seen at 12 week of gestation (Figs. 1C
and E). NOS was also expressed in the submucous fibres
from week 12 on (Fig. 1B). Double-labelling experiments
revealed a limited coexistence of VIPi with NOSi and NPYi
with NOSi depending on the embryonic age examined. NOSi
with VIPi or NOSi with NPYi were never expressed together
in the varicosities of the embryonic ENS. The dense varicos-
ities of peptidergic fibres expressed only VIP or NPY,
whereas the scarce varicosities containing NOS never ex-
pressed peptides. Three populations of immunoreactive cell
bodies were revealed after double-labelling with VIP and
NOS: a population of myenteric neurons co-expressing VIP
with NOS (Figs. 2C and D) and another two populations
containing VIP or NOS alone (Figs. 2C, D and Figs. 3E, F).
A population of nerve cell bodies in submucous ganglia were
observed that express VIPi and NOSi together from week 12
of gestation. Nerve cells after double-labelling with NPY and
NOS also fall into three classes: a population containing NPY
with NOS (Figs. 2A and B) and another two populations
expressing NPY or NOS alone (Figs. 2E and F). The number
of cell bodies expressing NPY alone or NPY and NOS
together were limited to one or two cells per ganglia.
Discussion
Our present investigations covered the localization of three
substances: NO, VIP and NPY, known to occur in neuronal
elements of human adult intestine. VIP-containing nerve
fibres occur abundantly in all layers of the human gut and
VIP nerve cell bodies are regularly observed in intramural
ganglia (Bishop et al. 1982). The presence of the regulatory
peptides and NO has been proved in the early human fetal
intestine (Bryant et al. 1982; Timmermans et al. 1994). Most
of the peptides studied throughout the fetal development had
an adult-like distribution pattern by weeks 20 and 24 of
gestation (Bloom et al. 1983). As well as having a regulatory
role in intestinal motility, relaxing smooth muscle and
mediating inhibitory non-adrenergic non-cholinergic
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Figure 1. Light photomicrographs of cross-sections of the human fetal gut wall after NOS (A, B), VIP (C, D, E) and NPY (F) immunocytochemistry
on week 12 of gestation.
A. NOS-immunopositive neuronal elements (arrowheads) are abundant both in the longitudinal (LM) and circular muscle (CM) layers. x200
B. NOS-immunopositive neuronal elements are present in myenteric ganglia (arrowheads). Smooth individual fibres in the submucous layer
(SM) with NOS-immunopositivity appear (arrows). x400
C. VIP-immunoreactive varicose fibres (arrowheads) and cell bodies (arrows) around glandular epithelia in the submucosal layer on week 12
of gestation. x650
D. VIP-immunoreactive varicose fibres form baskets around non-immunoreactive cell bodies (arrows) within a myenteric ganglion. Dense
array of VIP-immunoreactive fibres (arroheads) was also revealed in the circular muscle layer (CM). LM: longitudinal muscle layer, MG:
myenteric ganglion. x400
E. VIP-immunoreactive cell bodies (arrowheads) in the submucous plexus. CM: circular muscle layer, LM: longitudinal muscle layer, Ca: capillary,
x200
F. NPY-immunopositive neuronal elements in a myenteric ganglion (MG). x400
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Figure 2. Fluorescent micrographs of cross-sections (A-D) and wholemounts of the human fetal gut wall after double-labelling
immunocytochemistry for NOS, NPY (A, B, E, F) and NOS, VIP (C, D) on week 12 of gestation.
A. NOS-immunopositive neurons (arrow) in a myenteric ganglion (MG) and dense arrays of fluorescent fibres (arrowheads) in the musculature.
CM: circular muscle layer, LM: longitudinal muscle layer, x400
B. NPY-immunoreactive varicose fibres (arrows) in the circular muscle layer (CM) and in a myenteric ganglion. Some of the ganglion cells
coexpress NOS and NPY (arrowhead). The NPY-positive fibres form baskets around non-immunreactive myenteric neurons. x400
C. NOS-immunopositive neuronal elements in a myenteric ganglion. Most of the cells express NOS and VIP together (arrows), while others
express only NOS. x650
D. VIP-immunopositive neuronal elements in a myenteric ganglion. Most of the ganglion cells co-express NOS and VIP (arrows). x650
E. NOS-positive neurons in the myenteric plexus (arrows). x200
F. NPY-positive varicose fibres in the myenteric plexus. A nitrergic neuron (asterisk) is surrounded by NPY immunopositive fibres (arrows).
200x
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Figure 3. Fluorescent micrographs of wholemount preparations of the human fetal small intestine after single labelling immunocytochemistry
for NOS (A, C), VIP (B, D), and double labelling immunocytochemistry for NOS, VIP (E, F) on week 18 of gestation.
A. NOS-immunopositive neurons (arrowheads) in a myenteric ganglion. x400
B. Dense array of VIP-immunopositive varicose fibres (arrows) and cell bodies (arrowheads). x400
C. NOS-immunopositive neuronal cell bodies (arrowheads) in a myenteric ganglion. x1000
D. VIP-immunopositive neuronal cell body (arrowhead) in a myenteric ganglion. The immunoreactivity is unevenly distributed within the
perikaryon. x1000
E. NOS-immunopositive neuronal cell bodies (arrowheads) in a myenteric ganglion. x400
F. Dense array of the VIP-immunopositive varicose fibres (arrow) in the myenteric plexus. Varicose fibres frequently form baskets (asterisks)
around non-immunoreactive cell bodies. x400
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(NANC) neurotransmission (Larsson et al.1976; Furness et
al. 1992; Grider and Jin 1993; Allesher and Daniel 1994), the
ability to act as growth factors has also been demonstrated
both for NO (Ogura et al. 1996) and VIP (Gressens et al.
1993). In order to evaluate the potential interactions of NO,
VIP and NPY in the developing human fetal small intestine
double-labelling immunocytochemistry was used and simul-
taneous appearance of NOSi with VIPi and NPYi with NOSi
in the different neuronal structures was followed from week
12 of gestation, when immunoreactive neuronal elements
were widely distributed in the fetal ENS. While both VIP and
NPY were localized mainly to varicose fibres and they
frequently formed baskets around cell bodies, the majority
of fibres with NOSi were smooth and never formed baskets
around cell bodies. The number of cells expressing NOS was
higher in the MP than those expressing VIP, while in sub-
mucous ganglia the number of VIPi neuronal cell bodies
overwhelmed the one or two NOSi cells per ganglia. Due to
the high number of cells expressing VIP it can be assumed
that most of the fibres displaying VIPi are intrinsic of the fetal
gut. Both the peptidergic and the nitrergic neuronal structures
were less densely distributed in the SmP. However, varicos-
ities within the SmP with VIPi were not seen before week 18
of gestation, cells expressing VIP and NOS alone or together
appeared already at week 12. On the contrary, cellular
colocalization of NOSi and NPYi was not revealed within the
SmP; however, the scarce NOS immunreactive  neurons
frequently received NPY immunreactive fiber terminations
suggesting a modulatory role for NPY (Cox et al. 1998;
Feletou et al. 1998).
The coexistence of both VIPi with NOSi and NPY with
NOSi was most pronounced in the 18-week-old fetus, when
the pattern of colocalization is similar using either VIP or
NPY antibody in combination with NOS antibody. The
neurons which simultaneously expressed either VIP and NOS
or NPY and NOS fall into five groups, two populations
contained NOS and VIP or NOS and NPY together, another
populations contained NOS, VIP or NPY alone. The NOS
immunreactive neurons which have a dominant NPY inner-
vation might represent a subgroup of NOS neurons. The
physiological significance of this pattern of coexistence is
still a subject of debates. Due to the early expression of these
substances (Bryant et al. 1982; Chayvialle et al. 1983;
Larsson et al. 1987; Timmermans et al. 1994), they might
have their individual action during the early development,
relaxing smooth muscle (Costa et al. 1992; Grider and Jin
1993; Kirchgessner et al. 1994) and acting in NANC neuro-
transmission. Later in development, when oro-anal peristalsis
starts (Grand et al. 1976) and the motility of the gut needs a
more sophisticated regulation, a complementary role might
be presumed to these substances. NO may mediate the same
type of response as VIP or NPY but with a different time
course. The different classes of neurons suggest that in some
cases NO is the final transmitter but most of the cases it
probably serves as a modulator to another NANC neurotrans-
mitter or it has an effect on the regulation of development.
The lack of varicosities in submucous fibres expressing VIP
or NOS suggests that NANC inhibition is not an important
part of the submucous function in the early development of
human ENS. The early appearance of cellular colocalization
at the same time suggests a regulatory effect of these sub-
stances either in neurotransmission or in neuronal differenti-
ation.
In conclusion, the distribution and the pattern of coexist-
ence revealed in our present investigation using double-
labelling experiments with NOS and VIP or NOS and NPY
antibodies, strongly support the concept that VIP with NOS
and NPY with NOS are parallel neurotransmitters in the
human fetal small intestine, although the neurotrophic effect
of NO and VIP should be a subject of further investigation.
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